$RTGN
RetinalGenix Technologies Inc.

2024 Q1 Form 10-K Financial Statement

#000149315224012185 Filed on April 01, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.062M $486.8K $1.563M
YoY Change 631.79% 36.66% 46.51%
% of Gross Profit
Research & Development $83.10K $53.90K $524.2K
YoY Change -63.54% -83.04% -35.23%
% of Gross Profit
Depreciation & Amortization $25.00 $20.00 $100.00
YoY Change 0.0% 0.0% 96.08%
% of Gross Profit
Operating Expenses $2.145M $540.7K $2.087M
YoY Change 320.83% -19.78% -46.61%
Operating Profit
YoY Change
Interest Expense $960.00 -$960.00 $3.840K
YoY Change 0.0% 0.0% -25.29%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.146M -$541.6K -$2.091M
YoY Change 320.23% -19.75% -46.58%
Income Tax
% Of Pretax Income
Net Earnings -$2.146M -$541.6K -$2.091M
YoY Change 320.23% -19.75% -46.58%
Net Earnings / Revenue
Basic Earnings Per Share -$0.12 -$0.12
Diluted Earnings Per Share -$0.12 -$0.03 -$0.12
COMMON SHARES
Basic Shares Outstanding 17.79M shares 17.59M shares 17.35M shares
Diluted Shares Outstanding 17.67M shares 17.35M shares

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $50.39K $0.00 $0.00
YoY Change 574.56% -100.0% -100.0%
Cash & Equivalents $50.39K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $50.39K $0.00
YoY Change 574.51% -100.0%
LONG-TERM ASSETS
Property, Plant & Equipment $131.00 $156.00 $160.00
YoY Change -43.29% -39.06% -38.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $131.00 $156.00 $160.00
YoY Change -43.29% -39.06% -36.0%
TOTAL ASSETS
Total Short-Term Assets $50.39K $0.00
Total Long-Term Assets $131.00 $156.00 $160.00
Total Assets $50.52K $156.00 $160.00
YoY Change 555.98% -46.94% -44.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $813.6K $884.9K $884.9K
YoY Change 28.3% 86.11% 86.11%
Accrued Expenses $12.56K $11.60K $11.60K
YoY Change 44.04% 49.48% 49.48%
Deferred Revenue
YoY Change
Short-Term Debt $49.00K $49.00K $49.00K
YoY Change 0.0% 0.0% 0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.569M $1.406M $1.406M
YoY Change 4.01% 31.46% 31.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.569M $1.406M $1.406M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.569M $1.406M $1.406M
YoY Change 3.98% 31.52% 31.46%
SHAREHOLDERS EQUITY
Retained Earnings -$13.26M -$11.11M
YoY Change 39.1% 23.19%
Common Stock $1.786K $1.819K
YoY Change 0.17% 2.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.519M -$1.406M -$1.406M
YoY Change
Total Liabilities & Shareholders Equity $50.52K $156.00 $160.00
YoY Change 555.98% -46.94% -44.83%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$2.146M -$541.6K -$2.091M
YoY Change 320.23% -19.75% -46.58%
Depreciation, Depletion And Amortization $25.00 $20.00 $100.00
YoY Change 0.0% 0.0% 96.08%
Cash From Operating Activities -$142.9K -$186.7K -$348.4K
YoY Change 84.17% 461.65% 74.82%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $193.3K 186.7K $348.3K
YoY Change 127.34% 529.5% 78.93%
NET CHANGE
Cash From Operating Activities -$142.9K -186.7K -$348.4K
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities $193.3K 186.7K $348.3K
Net Change In Cash $50.39K -40.00 -$38.00
YoY Change 577.96% -98.89% -99.23%
FREE CASH FLOW
Cash From Operating Activities -$142.9K -$186.7K -$348.4K
Capital Expenditures $0.00 $0.00
Free Cash Flow -$186.7K -$348.4K
YoY Change 461.65% 74.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
usd
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
usd
CY2023 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
usd
CY2023 RGTS Acquired Inprocess Research And Development Through Issuance Of Common Stock
AcquiredInprocessResearchAndDevelopmentThroughIssuanceOfCommonStock
usd
CY2023 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
usd
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2023 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
CY2023 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2023 RGTS Offset Of Note Payable Affiliates Through The Exercise Of Warrants
OffsetOfNotePayableAffiliatesThroughTheExerciseOfWarrants
usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11109195 usd
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
shares
CY2022 RGTS Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceGranted
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
shares
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
15506590 usd
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17785478 shares
CY2023 dei Auditor Name
AuditorName
Liebman Goldberg & Hymowitz, LLP
CY2023 dei Auditor Location
AuditorLocation
Garden City, New York
CY2023 dei Auditor Firm
AuditorFirmId
473
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
38 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
151 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
51 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
156 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
256 usd
CY2023Q4 us-gaap Assets
Assets
156 usd
CY2022Q4 us-gaap Assets
Assets
294 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
884920 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
475480 usd
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
49000 usd
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
49000 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
7759 usd
CY2023Q4 us-gaap Liabilities
Liabilities
1405813 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1069357 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17635478 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17635478 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17272116 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17272116 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1819 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1783 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
9701719 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
7947460 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11109195 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9018306 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1405657 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1069063 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
156 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
294 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
898658 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
807406 usd
CY2023 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
524183 usd
CY2022 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
809255 usd
CY2022 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
2032889 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
664208 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
259300 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
2087049 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
3908850 usd
CY2023 us-gaap Interest Expense
InterestExpense
3840 usd
CY2022 us-gaap Interest Expense
InterestExpense
5140 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-2090889 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-3913990 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17352196 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17352196 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15584346 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15584346 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-464675 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
259300 usd
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
60500 usd
CY2022 RGTS Stock Issued During Period Value Warrant And Stock Options Exercised
StockIssuedDuringPeriodValueWarrantAndStockOptionsExercised
50000 usd
CY2022 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
939802 usd
CY2022 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
2000000 shares
CY2022 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
2000000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-3913990 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1069063 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1069063 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
664208 usd
CY2023 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
1090087 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-2090889 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1405657 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1405657 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-2090889 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-3913990 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
664208 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
259300 usd
CY2022 RGTS Acquired Inprocess Research And Development Through Issuance Of Common Stock
AcquiredInprocessResearchAndDevelopmentThroughIssuanceOfCommonStock
2000000 usd
CY2023 us-gaap Depreciation
Depreciation
100 usd
CY2022 us-gaap Depreciation
Depreciation
51 usd
CY2023 us-gaap Other Noncash Expense
OtherNoncashExpense
664914 usd
CY2022 us-gaap Other Noncash Expense
OtherNoncashExpense
1225014 usd
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
409440 usd
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
225198 usd
CY2023 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
3840 usd
CY2022 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
5140 usd
CY2023 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
1742502 usd
CY2022 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
3714703 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-348387 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-199287 usd
CY2022 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
307 usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
60500 usd
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
25000 usd
CY2023 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
348349 usd
CY2022 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
109185 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
348349 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
194685 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-38 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4909 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
38 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4947 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
0 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
38 usd
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2023 us-gaap Stock Issued1
StockIssued1
1090087 usd
CY2022 us-gaap Stock Issued1
StockIssued1
939802 usd
CY2022 RGTS Offset Of Note Payable Affiliates Through The Exercise Of Warrants
OffsetOfNotePayableAffiliatesThroughTheExerciseOfWarrants
25000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
1406000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1069000 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84E_eus-gaap--UseOfEstimates_zq9R1XTF7lq2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3. <span id="xdx_868_zThImK9u4jA">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing the Company’s consolidated financial statements in conformity with US GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000 shares
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
664208 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
259300 usd
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
341000 usd
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y9M18D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1882500 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.00
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
502500 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.00
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
25000 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.00
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
75000 shares
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.00
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2585000 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.23
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2585000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1204444 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2096111 shares
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.17
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0285 pure
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P1Y6M
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.80 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q4 us-gaap Share Price
SharePrice
3.00
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.56
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0219 pure
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y6M
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.80 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q4 us-gaap Share Price
SharePrice
1.00
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
199000 shares
CY2021Q4 RGTS Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
1.07
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
12500 shares
CY2022 RGTS Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price Cancelled
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceCancelled
1.00
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
25000 shares
CY2022 RGTS Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceExercised
1.00
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
161500 shares
CY2022Q4 RGTS Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
1.09
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
11500 shares
CY2023 RGTS Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price Cancelled
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceCancelled
1.00
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
150000 shares
CY2023Q4 RGTS Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
1.10
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.10
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
150000 shares
CY2023 RGTS Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms
P4Y3M18D
CY2023Q4 RGTS Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
150000 shares
CY2021Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
74000 usd
CY2021Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.08 pure
CY2021 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2022-12-31
CY2021 RGTS Debt Instrument Extended Maturity Date
DebtInstrumentExtendedMaturityDate
2024-12-31
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
25000 usd
CY2023Q4 us-gaap Notes Payable
NotesPayable
49000 usd
CY2022Q4 us-gaap Notes Payable
NotesPayable
49000 usd
CY2023 us-gaap Interest Expense Debt
InterestExpenseDebt
3840 usd
CY2022 us-gaap Interest Expense Debt
InterestExpenseDebt
5140 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
11599 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
7759 usd
CY2023 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
the Company had net operating loss carryforwards (“NOL”) of approximately $5,500,000 for federal income tax purposes of which $4.725,000 has no expiration date, $775,000 which begins to expire in 2034, and approximately $5,400,000 for state income tax purposes which begins to expire in 2030.
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
5500000 usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3316000 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1650000 usd
CY2023Q4 RGTS Deferred Tax Assets Applicable To Accruals
DeferredTaxAssetsApplicableToAccruals
444000 usd
CY2023Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
610000 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
612000 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2690000 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1372000 usd
CY2022Q4 RGTS Deferred Tax Assets Applicable To Accruals
DeferredTaxAssetsApplicableToAccruals
244000 usd
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
610000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
464000 usd
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
626000 usd
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1511000 usd

Files In Submission

Name View Source Status
0001493152-24-012185-index-headers.html Edgar Link pending
0001493152-24-012185-index.html Edgar Link pending
0001493152-24-012185.txt Edgar Link pending
0001493152-24-012185-xbrl.zip Edgar Link pending
ex21-1.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex4-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-k.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
form10-k_htm.xml Edgar Link completed
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgts-20231231.xsd Edgar Link pending
Show.js Edgar Link pending
rgts-20231231_def.xml Edgar Link unprocessable
rgts-20231231_lab.xml Edgar Link unprocessable
rgts-20231231_pre.xml Edgar Link unprocessable
rgts-20231231_cal.xml Edgar Link unprocessable